1.17
price down icon4.88%   -0.06
after-market Handel nachbörslich: 1.23 0.06 +5.13%
loading
Schlusskurs vom Vortag:
$1.23
Offen:
$1.22
24-Stunden-Volumen:
143.40K
Relative Volume:
0.46
Marktkapitalisierung:
$16.93M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.29M
KGV:
-1.6714
EPS:
-0.7
Netto-Cashflow:
$-6.47M
1W Leistung:
-2.50%
1M Leistung:
-23.53%
6M Leistung:
-40.91%
1J Leistung:
+0.86%
1-Tages-Spanne:
Value
$1.16
$1.2382
1-Wochen-Bereich:
Value
$1.1221
$1.35
52-Wochen-Spanne:
Value
$1.0297
$3.59

NanoViricides Inc Stock (NNVC) Company Profile

Name
Firmenname
NanoViricides Inc
Name
Telefon
203-937-6137
Name
Adresse
1 Controls Drive, Shelton, CT
Name
Mitarbeiter
7
Name
Twitter
@nnvcnyse
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
NNVC's Discussions on Twitter

Vergleichen Sie NNVC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
NNVC
NanoViricides Inc
1.17 16.93M 0 -8.29M -6.47M -0.70
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.32 122.13B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
710.00 78.30B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
646.64 39.73B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
276.19 35.50B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.61 28.47B 3.30B -501.07M 1.03B -2.1146

NanoViricides Inc Stock (NNVC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2015-02-11 Eingeleitet Midtown Partners Strong Buy

NanoViricides Inc Aktie (NNVC) Neueste Nachrichten

pulisher
Feb 05, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Feb 05, 2025
pulisher
Feb 05, 2025

NNVC’s price-to-cash ratio: Is it a good investment at the moment? - US Post News

Feb 05, 2025
pulisher
Feb 04, 2025

NanoViricides seeks to eliminate treatment delays with its broad spectrum antiviral NV-387 - Proactive financial news

Feb 04, 2025
pulisher
Jan 31, 2025

NanoViricides warns of bird flu pandemic as outbreak spreads in Massachusetts - Proactive Investors UK

Jan 31, 2025
pulisher
Jan 30, 2025

NanoViricides (NYSE:NNVC) Trading Down 1.8% – What’s Next? - Defense World

Jan 30, 2025
pulisher
Jan 29, 2025

NanoViricides to present at MicroCap Conference 2025 in Atlantic City - Proactive Investors UK

Jan 29, 2025
pulisher
Jan 29, 2025

Game-Changing Antiviral Drug Shows 'Superior Results' Against Multiple Viruses$10B Market Potential - StockTitan

Jan 29, 2025
pulisher
Jan 28, 2025

NanoViricides advances antiviral drug with Phase II Clinical trial to Combat MPox - Proactive Investors USA

Jan 28, 2025
pulisher
Jan 27, 2025

NanoViricides taps clinical research organization for Phase II trial of NV-387 - Proactive Investors UK

Jan 27, 2025
pulisher
Jan 27, 2025

NanoViricides Engages CRO for Phase II Clinical Trial - Oil City Derrick

Jan 27, 2025
pulisher
Jan 13, 2025

NanoViricides to present antiviral drug pipeline at Biotech Showcase 2025 - Proactive Investors Australia

Jan 13, 2025
pulisher
Jan 13, 2025

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025 - Oil City Derrick

Jan 13, 2025
pulisher
Jan 12, 2025

NanoViricides CEO discusses NV-387’s broad spectrum promiseICYMI - Proactive Investors Australia

Jan 12, 2025
pulisher
Jan 08, 2025

NanoViricides highlights urgent need for broad-spectrum antiviral solutions amid viral threats - Proactive Investors Australia

Jan 08, 2025
pulisher
Jan 08, 2025

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals - AccessWire

Jan 08, 2025
pulisher
Jan 08, 2025

NanoViricides (NYSE:NNVC) Trading Down 5% – Should You Sell? - Defense World

Jan 08, 2025
pulisher
Jan 07, 2025

First US bird flu fatality raises alarms over mutations in H5N1 virus - Proactive Investors USA

Jan 07, 2025
pulisher
Jan 07, 2025

NanoViricides CEO discusses groundbreaking broad-spectrum antiviral treatment - Proactive Investors UK

Jan 07, 2025
pulisher
Dec 27, 2024

NanoViricides, Inc. Files Quarterly ReportReports a Strong Cash Position Sufficient for Initial C - AOL

Dec 27, 2024
pulisher
Dec 23, 2024

NanoViricides sees NV-387 as a key defense against bird flu pandemic - Proactive Investors UK

Dec 23, 2024
pulisher
Dec 23, 2024

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape - Oil City Derrick

Dec 23, 2024
pulisher
Dec 23, 2024

NanoViricides' NV-387 Shows Breakthrough 88% Survival Rate Against H5N1 Bird Flu in Key Study - StockTitan

Dec 23, 2024
pulisher
Dec 09, 2024

NanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North America By Proactive Investors - Investing.com UK

Dec 09, 2024
pulisher
Dec 06, 2024

NanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North America - Proactive Investors UK

Dec 06, 2024
pulisher
Nov 29, 2024

NanoViricides: Pioneering the Future of Antiviral Therapies - TechBullion

Nov 29, 2024
pulisher
Nov 26, 2024

NanoViricides (AMEX:$NNVC) Leads Innovation In Broad-Spectrum Antiviral Therapies - Barchart

Nov 26, 2024
pulisher
Nov 26, 2024

NanoViricides (AMEX:$NNVC) Leads Innovation in Broad-Spectrum Antiviral Therapies - openPR

Nov 26, 2024
pulisher
Nov 20, 2024

NanoViricides (NYSE:NNVC) Rating Lowered to “Sell” at StockNews.com - Defense World

Nov 20, 2024
pulisher
Nov 16, 2024

NanoViricides pushes NV-387 to Phase II trials - Proactive Investors Australia

Nov 16, 2024
pulisher
Nov 15, 2024

NanoViricides' Antiviral Drug NV-387 Advances to Phase II Trials Amid Funding Needs - StockTitan

Nov 15, 2024
pulisher
Nov 15, 2024

NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical TrialMultiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID - Source ONE News

Nov 15, 2024
pulisher
Nov 15, 2024

NanoViricides Inc (NNVC) Quarterly 10-Q Report - Quartz

Nov 15, 2024
pulisher
Nov 15, 2024

NanoViricides pushes NV-387 to Phase II trials | NYSE-A:NNVC - Proactive Investors USA

Nov 15, 2024
pulisher
Nov 14, 2024

NanoViricides: Fiscal Q1 Earnings Snapshot - San Antonio Express-News

Nov 14, 2024
pulisher
Nov 04, 2024

NanoViricides to update on broad-spectrum antiviral drug at Spartan Capital Investors Conference - Proactive Investors Australia

Nov 04, 2024
pulisher
Nov 04, 2024

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am - Oil City Derrick

Nov 04, 2024
pulisher
Oct 22, 2024

NanoViricides exec to showcase breakthrough antiviral technology at PODD Conference - Proactive financial news

Oct 22, 2024
pulisher
Oct 22, 2024

NanoViricides President Dr. Diwan to Present at the PODD Conference - News-Press Now

Oct 22, 2024
pulisher
Oct 22, 2024

NanoViricides exec to showcase breakthrough antiviral technology at PODD Conference | NYSE-A:NNVC - Proactive Investors USA

Oct 22, 2024
pulisher
Oct 21, 2024

Can NanoViricides Inc (NNVC) Stock Rise to the Top of Healthcare Sector Tuesday? - InvestorsObserver

Oct 21, 2024
pulisher
Oct 20, 2024

Interview with the President and Executive Chairman: NanoViricides, Inc. (NYSEAMERICAN:NNVC) - The Wall Street Transcript

Oct 20, 2024
pulisher
Oct 18, 2024

NNVC - Insider Financial

Oct 18, 2024
pulisher
Oct 16, 2024

Chronic Fatigue Syndrome Market Demand and Opportunities - openPR

Oct 16, 2024
pulisher
Oct 15, 2024

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology - Oil City Derrick

Oct 15, 2024
pulisher
Oct 14, 2024

Renaissance Technologies LLC Boosts Position in NanoViricides, Inc. (NYSE:NNVC) - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy - Insider Monkey

Oct 14, 2024
pulisher
Oct 09, 2024

7 Best Nanotech Penny Stocks to Buy - Insider Monkey

Oct 09, 2024

Finanzdaten der NanoViricides Inc-Aktie (NNVC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$74.13
price down icon 1.09%
$20.11
price down icon 2.71%
$347.71
price down icon 1.71%
$4.69
price down icon 6.94%
biotechnology ONC
$223.50
price down icon 2.35%
$117.61
price down icon 1.94%
Kapitalisierung:     |  Volumen (24h):